A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Aliskiren (Primary)
- Indications Hypertension
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Novartis
- 27 Aug 2014 Status changed from recruiting to completed according to ClinicalTrials.gov record.
- 15 Apr 2014 Planned End Date changed from 1 Jun 2014 to 1 Aug 2014, as per ClinicalTrials.gov record.
- 25 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.